Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Publication Date: May 30, 2022
Last Updated: May 31, 2022
Treatment
HER2+
First-Line
Recommendation 1.0
Clinicians should recommend HER2-targeted therapy-based combinations for first-line treatment, except for highly selected patients with estrogen receptor-positive (ER+) or progesterone receptor-positive (PgR+) and HER2-positive disease for whom clinicians may use endocrine therapy alone. (EB, , H, S)
1048203
Recommendation 1.1
Clinicians should recommend the combination of trastuzumab, pertuzumab, and a taxane for first-line treatment, unless the patient has a contraindication to taxanes. (EB, B, H, S)
1048203
Second-Line
Recommendation 2.0
If a patient’s HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy, clinicians should recommend second-line HER2-targeted therapy-based treatment. (EB, , H, S)
1048203
Recommendation 2.1 (updated)
If a patient’s HER2-positive advanced breast cancer has progressed during or after first-line HER2-targeted therapy (and the patient has not received trastuzumab deruxtecan), clinicians should recommend trastuzumab deruxtecan as a second-line treatment. (EB, B, M, S)
1048203
Third-Line
Recommendation 3.0
If a patient’s HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted treatment, clinicians should recommend third-line or greater-line HER2-targeted therapy-based treatment. (EB, , I, M)
1048203
Overall, there are a lack of head-to-head trials, therefore there is insufficient evidence to recommend one regimen over another. The patient and clinician should discuss differences in treatment schedules, routes, and toxicities during the decision-making process.
Options include the following:
Options include the following:
Recommendation 3.1 (updated)
If a patient’s HER2-positive advanced breast cancer has progressed during or after second-line or greater HER2-targeted treatment and the patient has already received pertuzumab and trastuzumab deruxtecan, clinicians should recommend third-line or greater HER2-targeted therapy-based treatment. (, , , )
1048203
Recommendation 3.1.1 (updated)
If a patient has not received trastuzumab emtansine (T-DM1) in second-line, should offer T-DM1 regimen. (EB, B, H, S)
1048203
Recommendation 3.1.2 (updated)
May offer tucatinib combined with trastuzumab and capecitabine. (EB, B, M, S)
1048203
Recommendation 3.1.3 (updated)
May offer trastuzumab deruxtecan. (EB, B, M, S)
1048203
Recommendation 3.1.4 (updated)
May offer neratinib combined with capecitabine. (EB, B, M, W)
1048203
Recommendation 3.1.5
May offer lapatinib and trastuzumab. (EB, B, M, W)
1048203
Recommendation 3.1.6
May offer lapatinib and capecitabine. (EB, B, M, W)
1048203
Recommendation 3.1.7
May offer other combinations of chemotherapy and trastuzumab. (EB, B, M, W)
1048203
Recommendation 3.1.8 (updated)
May offer margetuximab plus chemotherapy. (EB, B, M, W)
1048203
Recommendation 3.1.9
If a patient has not received pertuzumab, clinicians may offer pertuzumab. (IC, B, Ins, W)
1048203
Recommendation 3.2.0
May offer hormonal therapy (in patients with ER+ and/or PgR+ disease). (EB, B, M, W)
1048203
Recommendation 3.2.1 (updated)
May offer abemaciclib combined with trastuzumab and fulvestrant. (EB, B, M, W)
1048203
Timing, Dose, Schedule, and Duration
Recommendation 4.0
If a patient is receiving HER2-targeted therapy and chemotherapy combinations, the chemotherapy should continue for approximately 4–6 months (or longer) and/or to the time of maximal response, depending on toxicity and in the absence of progression. When chemotherapy is stopped, clinicians should continue the HER2-targeted therapy; no further change in the regimen is needed until the time of progression or unacceptable toxicities. (EB, , I, M)
1048203
Recurrence
Recommendation 5.0
If a patient finished trastuzumab-based adjuvant treatment ≤12 months before recurrence, clinicians should follow the second-line HER2-targeted therapy-based treatment recommendations. (EB, , I, M)
1048203
Recommendation 5.1
If a patient finished trastuzumab-based adjuvant treatment >12 months before recurrence, clinicians should follow the first-line HER2-targeted therapy-based treatment recommendations. (EB, , H, S)
1048203
HER2+, ER+, PgR+
First-Line
Recommendation 6.0
If a patient’s cancer is hormone receptor-positive and HER2-positive, clinicians may recommend either: (, , , )
1048203
Recommendation 6.0.1
HER2-targeted therapy plus chemotherapy. (EB, , H, S)
1048203
Recommendation 6.0.2
Endocrine therapy plus trastuzumab or lapatinib (in selected cases). (EB, , M, S)
1048203
Recommendation 6.0.3
Endocrine therapy alone (in selected cases). (EB, , I, W)
1048203
Endocrine Therapy Sequencing
Recommendation 7.0
If the patient has started with a HER2-positive targeted therapy and chemotherapy combination, clinicians may add endocrine therapy to the HER2-targeted therapy when chemotherapy ends and/or when the cancer progresses. (IC, , Ins, W)
1048203
First-Line Endocrine Therapy
Recommendation 8.0
In special circumstances, such as low disease burden, the presence of co-morbidities (contradictions to HER2-targeted therapy such as congestive heart failure), and/or the presence of a long disease free-interval, clinicians may offer first-line endocrine therapy alone. (IC, , Ins, W)
Qualifying Statement: Although the clinician may discuss using endocrine therapy with or without HER2-targeted, the majority of patients should still receive chemotherapy plus HER2-targeted therapy.
1048203
Recommendation Grading
Overview
Title
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Authoring Organization
American Society of Clinical Oncology
Publication Month/Year
May 30, 2022
Last Updated Month/Year
October 1, 2024
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
The purpose of this guideline update is to provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding guidance for optimal management of patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer (MBC).
Target Patient Population
Individuals with advanced HER2-positive breast cancer.
Target Provider Population
Medical oncologists, radiation oncologists, surgeons, oncology nurses
PICO Questions
What is the optimal treatment for patients with HER2-positive advanced breast cancer?
What is the optimal medical therapy for advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer in combination with chemotherapy and/or endocrine therapy?
Inclusion Criteria
Female, Adult, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment
Diseases/Conditions (MeSH)
D001943 - Breast Neoplasms
Keywords
breast cancer, human epidermal growth factor receptor 2 (HER2), Advanced Breast Cancer, HER2, HER2 Positive
Source Citation
Giordano SH, Franzoi MB, Temin S, et al. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022 May 31. doi: 10.1200/JCO.22.00519.
Supplemental Methodology Resources
Methodology
Number of Source Documents
51
Literature Search Start Date
July 31, 2016
Literature Search End Date
March 31, 2021